A Missouri Republican lawmaker filed a bill on Tuesday that would legalize a wide range of psychedelics for therapeutic use at designated care facilities while further decriminalizing low-level possession in general.
Exploring the companies and themes that make up this emerging and exciting new sector
Field Trip Health and Cerebral Partner to Provide End-to-End Mental Health Care
Field Trip Health announces a strategic partnership with Cerebral, "the fastest growing online mental health platform".
MindMed Announces Publication of Study Comparing the Acute Effects of LSD and Psilocybin in Healthy Subjects
MindMed announced the peer-reviewed publication of a study directly comparing the acute effects of LSD and psilocybin in healthy subjects.
Enveric Biosciences Files Portfolio of Patent Applications for Tryptamine-Based Molecules
Enveric Biosciences announces the filing of its 10th patent application for its tryptamine-based molecules.
Red Light Holland Reports Fiscal Third Quarter Results
Red Light Holland reports quarterly revenue growth of 28% and gross profit growth of 48% for Q3 of fiscal 2022. Strong cash position of CAD$27.3 million.
Novamind Reports Fiscal Q2 2022 Financial Results and Operating Highlights
Novamind reports 32% q-o-q revenue growth, up to CAD $2.45 million in its latest quarter. Cash balance of ~CAD$8 million including post-period financing.
Mydecine Reports Positive Pre-IND Meeting With FDA For MYCO-001 Smoking Cessation Study
Mydecine prepares to submit its IND and application for Breakthrough Therapy Status for smoking cessation after successful meeting with FDA.
Revitalist Receives Approval from Biomedical Research Alliance of New York Permitting the Company to Perform Human Subjects Clinical Trials
Revitalist obtains regulatory approval for its clinics to host human clinical trials for psychedelics-based therapies.
Why Microdosing Cannot Replace Psychedelic Medicine
Psychedelic medicine is proving it can provide spectacular treatment results for many mental health disorders. Microdosing may also be an important therapy tool. But there's a catch.
COMPASS Pathways announces financial results for the fourth quarter and full year 2021 and business highlights
COMPASS Pathways reported its financial results for the fourth quarter and full year 2021 and gave an update on recent progress across its business.
Pasithea Therapeutics Announces Plans to Open Three New Clinics in the UK by Mid-2022
Pasiethea Therapeutics plans to offer three new clinics offering both ketamine-based and "repeated transcranial magnetic stmulation" treatments (rTMS).
Optimi Health Launches E-Commerce Platform Featuring All-Natural Functional Mushroom Supplements
Optimi Health announces the launch of six nootropic supplements derived from functional mushrooms.